Literature DB >> 20725943

Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.

Laurent Peyrin-Biroulet1, Edward V Loftus, Jean-Frederic Colombel, William J Sandborn.   

Abstract

BACKGROUND: Crohn's disease (CD) is a chronic, progressive, destructive disease. Numerous intestinal and extraintestinal complications and manifestations can occur during its clinical course. This literature review summarizes our current knowledge of the long-term complications, extraintestinal complications, and mortality in CD in adults as reported in population-based studies that include long-term follow-up results.
METHODS: A literature search of English and non-English language publications listed in the electronic databases of Medline (source PubMed, 1935 to July, 2009).
RESULTS: The relative risk of incident fractures is increased in CD patients by ≈30%-40%. These patients have also have a 3-fold increased risk of deep venous thrombosis and pulmonary embolism. A variety of extraintestinal manifestations (primary sclerosing cholangitis, ankylosing spondylitis, iritis/uveitis, pyoderma gangrenosum, erythema nodosum) and diseases (asthma, bronchitis, pericarditis, psoriasis, rheumatoid arthritis, and multiple sclerosis) are associated with CD. The risks of colorectal and small bowel cancers relative to the general population are 1.4-1.9 and 21.1-27.1, respectively. A slightly increased risk of lymphoma, irrespective of medication use, has been reported in a recent meta-analysis of population-based studies. Overall mortality is slightly increased in CD, with a standardized mortality ratio of 1.4.
CONCLUSIONS: CD is frequently associated with disease complications and extraintestinal conditions. Whether the impact of changing treatment paradigms with increased use of immunosuppressives and biologic agents can reduce disease complications and associated conditions is unknown.
Copyright © 2010 Crohn's & Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20725943     DOI: 10.1002/ibd.21417

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  54 in total

1.  Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.

Authors:  Konstantinos Karmiris; Anastasios Avgerinos; Aikaterini Tavernaraki; Christos Zeglinas; Pantelis Karatzas; Theodoros Koukouratos; Konstantinos A Oikonomou; Athanasios Kostas; Evanthia Zampeli; Vasileios Papadopoulos; Angeliki Theodoropoulou; Nikos Viazis; Dimitrios Polymeros; Spyridon Michopoulos; Giorgos Bamias; Andreas Kapsoritakis; Dimitrios G Karamanolis; Gerassimos J Mantzaris; Charalampos Tzathas; Ioannis E Koutroubakis
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

Review 2.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

3.  Diagnostic delay in patients with inflammatory bowel disease in Austria.

Authors:  Gottfried Novacek; Hans Peter Gröchenig; Thomas Haas; Heimo Wenzl; Pius Steiner; Robert Koch; Thomas Feichtenschlager; Gerald Eckhardt; Andreas Mayer; Andreas Kirchgatterer; Othmar Ludwiczek; Reingard Platzer; Pavol Papay; Johanna Gartner; Harry Fuchssteiner; Wolfgang Miehsler; Paul-Gerhard Peters; Gerhard Reicht; Harald Vogelsang; Clemens Dejaco; Thomas Waldhör
Journal:  Wien Klin Wochenschr       Date:  2019-02-04       Impact factor: 1.704

4.  A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation.

Authors:  David Padua; Swapna Mahurkar-Joshi; Ivy Ka Man Law; Christos Polytarchou; John P Vu; Joseph R Pisegna; David Shih; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-04       Impact factor: 4.052

Review 5.  Cytokines in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

6.  Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Authors:  Meenakshi Bewtra; Lisa M Kaiser; Tom TenHave; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

Review 7.  Antisense approach to inflammatory bowel disease: prospects and challenges.

Authors:  Irene Marafini; Davide Di Fusco; Emma Calabrese; Silvia Sedda; Francesco Pallone; Giovanni Monteleone
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 8.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 9.  First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

Authors:  Laurent Peyrin-Biroulet; Gionata Fiorino; Anthony Buisson; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

10.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.